Last edition
News about "XYRA"
XYRA receives a US patent protecting dose-adjusted budiodarone therapy for atrial fibrillation, aiming to reduce stroke and heart failure risk through patient monitoring while offering a safer rhythm-control option.
XYRA | 06/03/2026 | By News Bureau | 142
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members